CET

Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathy

Retrieved on: 
Friday, November 24, 2023
National Medical Products Administration, NDA, HKEX, Sustainability, ASN, Prevalence, CALT, Risk, NMPA, Disease, American Society of Nephrology, Patient, CET, Mount Everest, New Drug Application, EGFR, Microhematuria, Society, HIV disease progression rates, Proteinuria, Pharmaceutical industry, IgA nephropathy

China has the highest prevalence of primary glomerular diseases in the world with an estimated five million IgAN patients.

Key Points: 
  • China has the highest prevalence of primary glomerular diseases in the world with an estimated five million IgAN patients.
  • There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian countries.
  • Everest also announced that, in addition to Nefecon's approval in mainland China and Macau, it expects a decision on New Drug Application (NDA) approval in Singapore and Hong Kong in the near term.
  • This approval triggers a milestone payment of five million USD to Calliditas, which will be included as revenue in the fourth quarter.

Medivir to present at the Redeye Life Science Day

Retrieved on: 
Wednesday, November 22, 2023
Nasdaq Stockholm, Drug development, CET, Patient, Partnership, Market capitalization, Cancer, Red eye, SMAC, Pharmaceutical industry, Medivir

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.

Key Points: 
  • STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.
  • CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Implantica publishes Interim Report January - September 2023 (Q3)

Retrieved on: 
Wednesday, November 22, 2023
ID, Mary, mother of Jesus, Corporate Affairs, Safety, Food, CFO, Saint Mary's Hospital, GERD, Investment, EFS, Surgeon, Nissen fundoplication, Learning, Vienna General Hospital, Patient, CET, Congress, FDA, ARB, NHS, AFS, Food and Drug Administration, Usability, IPAC, Certification, ISPOR, Health, Hospital, PMA, Hernia, Pharmaceutical industry, Medical device

The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.

Key Points: 
  • The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™.
  • The IPAC review process is a key step for NHS hospitals to adopt our technology with strong international influence.
  • Implantica will hold a teleconference on 22 November 2023 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer).
  • The information was submitted for publication, through the agency of the contact person set out above, at 2023-11-22 08:00 CET.

Desert Control releases its Q3 2023 Report and Year-to-Date Company Update

Retrieved on: 
Wednesday, November 22, 2023
Webcast, Central European, LNC, NOK, Q3, CET, Interim

SANDNES, Norway, Nov. 22, 2023 /PRNewswire/ -- Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023.

Key Points: 
  • Desert Control concluded the third quarter with a strengthened financial position and continued consistent execution.
  • SANDNES, Norway, Nov. 22, 2023 /PRNewswire/ -- Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023.
  • Webcast presentation for Desert Control Q3 2023 Report and Interim Financial Results hosted on 22 November 2023 at 10:00 AM, Central European Time (CET).
  • Register: go.desertcontrol.com/Q3-2023
    The Q3 report, company update presentation, recording and transcript of the webcast will be made available on the company website: www.desertcontrol.com/investors under the archive section.

Desert Control releases its Q3 2023 Report and Year-to-Date Company Update

Retrieved on: 
Wednesday, November 22, 2023
Webcast, Central European, LNC, NOK, Q3, CET, Interim

SANDNES, Norway, Nov. 22, 2023 /PRNewswire/ -- Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023.

Key Points: 
  • Desert Control concluded the third quarter with a strengthened financial position and continued consistent execution.
  • SANDNES, Norway, Nov. 22, 2023 /PRNewswire/ -- Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023.
  • Webcast presentation for Desert Control Q3 2023 Report and Interim Financial Results hosted on 22 November 2023 at 10:00 AM, Central European Time (CET).
  • Register: go.desertcontrol.com/Q3-2023
    The Q3 report, company update presentation, recording and transcript of the webcast will be made available on the company website: www.desertcontrol.com/investors under the archive section.

Implantica's RefluxStopTM, a promising new procedure for chronic acid reflux, offered for the first time in the NHS in UK

Retrieved on: 
Tuesday, November 21, 2023
Cough, Depression, Stomach, Kidney disease, Risk, Food, Patient, CET, Saint Mary's Hospital, University of York, NHS, St. Mary's, Trust, Certification, Catherine Disher, Consultant, GORD, Pain, Insomnia, Quality of life, Mary, mother of Jesus, Asthma, Hospital, Nursing, Health insurance

Four patients with GORD underwent the RefluxStop™ procedure in early September at St Mary's hospital, part of Imperial College Healthcare NHS Trust.

Key Points: 
  • Four patients with GORD underwent the RefluxStop™ procedure in early September at St Mary's hospital, part of Imperial College Healthcare NHS Trust.
  • All had minimally invasive, keyhole surgery, were quickly discharged from hospital and have made an excellent recovery.
  • Approximately 20% of the adult UK population have problems with severe acid reflux[1] or GORD.
  • We are pleased to announce that this landmark achievement of the first surgeries in NHS UK have now taken place.

Photocure to present at four investor conferences in November/December 2023

Retrieved on: 
Monday, November 20, 2023
PHO, CET, Bladder cancer, Conference, Photocure, Cryptocurrency

OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

Key Points: 
  • OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
    The SEB Healthcare Seminar will take place in Stockholm, November 21-23, 2023.
  • David Moskowitz, Photocure's Vice President Investor Relations will present a corporate overview on November 22 at 10:40am CET.
  • The 35th Annual Piper Sandler Healthcare Conference will be held in New York City, November 28-30, 2023.
  • The 14th Annual DNB Nordic Healthcare Conference will be held in Oslo on December 14, 2023.

Photocure to present at four investor conferences in November/December 2023

Retrieved on: 
Monday, November 20, 2023
PHO, CET, Bladder cancer, Conference, Photocure, Cryptocurrency

OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:

Key Points: 
  • OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
    The SEB Healthcare Seminar will take place in Stockholm, November 21-23, 2023.
  • David Moskowitz, Photocure's Vice President Investor Relations will present a corporate overview on November 22 at 10:40am CET.
  • The 35th Annual Piper Sandler Healthcare Conference will be held in New York City, November 28-30, 2023.
  • The 14th Annual DNB Nordic Healthcare Conference will be held in Oslo on December 14, 2023.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.

Lecanemab winner in two categories at The Scrip Awards 2023

Retrieved on: 
Monday, November 20, 2023
Research, Pathology, Clinical trial, Patient, CET, Eisai, Alzheimer's disease, Co-promotion, Scrip, Boxed, HIV disease progression rates, Pharmaceutical industry, Biogen

STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.

Key Points: 
  • STOCKHOLM, Nov. 20, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) invention lecanemab (LEQEMBI®), partnered with Eisai, was awarded the Best New Drug and the award for the Clinical Advance of the Year at the Scrip Awards 2023.
  • The Scrip Awards celebrate the best innovations and achievements of the international biopharma industry.
  • It was awarded for the success of the Phase 3 Clarity AD study of lecanemab.
  • The information was released for public disclosure, through the agency of the contact persons below, on November 20, 2023, at 08.30 a.m. CET.